Press release
Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Rapidly Increasing In Size Globally (2020-2025) and Market Analysis by Gilead, Biopredictive, Quest Diagnostics, Exalenz Bioscience, GENFIT
Non-alcoholic Steatohepatitis (NASH) Biomarkers Market
The report covers a forecast and an analysis of the Non-alcoholic Steatohepatitis (NASH) Biomarkers Market on a global and regional level. The study provides historical data for 2015, 2016, 2017 and 2018 along with a forecast from 2020 to 2025 based on revenue (USD Million) and volume (Kilotons). The study includes drivers and restraints of the Non-alcoholic Steatohepatitis (NASH) Biomarkers Market along with the impact they have on the demand over the forecast period.
Most important key factors driving the growth of the Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market are rapid growth in prevalence of NAFLD & NASH disease; large unmet needs in terms of disease epidemiology and available diagnostic and therapeutic tools; increasing demand for non-invasive diagnostic methods; rising geriatric population; growing incidences of obesity and type 2 diabetes; awareness about diagnostic tools; and shift of government focus toward providing better healthcare facilities.
Available Exclusive Sample Copy of this Report @ https://www.businessindustryreports.com/sample-request/267993 .
On the basis of regional analysis, North America dominated the Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market in 2018, followed by Europe. North America accounted for major share of the Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market in 2018. This can be attributed to the large patient pool suffering from NASH and NAFLD indication, along with increasing liver diseases. Increasing prevalence of obesity and Type 2 diabetes, rise in demand of non-invasive diagnostic tool such as biomarkers, and adoption of emerging and innovative biomarkers are few major attributable factors for the Non-alcoholic Steatohepatitis (NASH) Biomarkers Market.
This report contains a complete product overview and its scope in the market to define the key terms and provide the clients a holistic idea of the market and its tendency. It comprehensively evaluates the Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market with different perspectives for the purpose of providing a detailed, informative, and accurate analysis of regional growth, competition, market segmentation, and other important aspects.
Global Key Players:
1 Biopredictive
2 Quest Diagnostics
3 Exalenz Bioscience
4 GENFIT
5 Siemens Healthineers
6 ONE WAY LIVER
7 Prometheus Laboratories
8 Gilead Sciences and More……………….
Purchase this report online with 90 Pages, List of Tables & Figures and in-depth Table of Contents on “Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Report 2020” @ https://www.businessindustryreports.com/buy-now/267993/single .
Product Type Segmentation
1 Serum Biomarkers
2 Cytokeratin-18 (CK 18) Marker
3 Inflammatory Markers
Industry Segmentation
1 Hospitals
2 Diagnostic Centers
On the basis of Regional analysis, North America and Europe holds major share in global Non-alcoholic Steatohepatitis (NASH) Biomarkers market. Moreover, Asia-Pacific is expected to record higher growth rate in Non-alcoholic Steatohepatitis (NASH) Biomarkers Market during the forecast year.
Global Medical Industry News:
Gilead Sciences (May 20, 2020) - Gilead and Galapagos Announce Positive Topline Results of Phase 2b/3 Trial of Filgotinib in Moderately to Severely Active Ulcerative Colitis - Gilead Sciences, Inc. and Galapagos NV today announced positive topline results from SELECTION, a randomized, double-blind, placebo-controlled, Phase 2b/3 trial evaluating the efficacy and safety of the investigational, oral, once-daily, selective JAK1 inhibitor filgotinib in 1,348 biologic-naïve or biologic-experienced adult patients with moderately to severely active ulcerative colitis (UC). Filgotinib 200 mg achieved all primary endpoints in the study, inducing clinical remission at Week 10 and maintaining clinical remission at Week 58 in a significantly higher proportion of patients compared with placebo. Filgotinib 100 mg did not achieve statistically significant clinical remission at Week 10.
In this trial, clinical remission was defined as endoscopic subscore of 0 or 1, rectal bleeding subscore of 0 and greater than or equal to 1 point decrease in stool frequency from baseline to achieve subscore of 0 or 1. Among the biologic-naïve cohort (Cohort A induction trial; n=659), 52 percent of patients had a baseline Mayo Clinic Score (MCS) of nine or higher. In the biologically-experienced cohort (Cohort B induction trial; n=689), 74 percent of patients had a baseline MCS of nine or higher, and 51 percent were previously treated with two different classes of biologics (TNFα antagonists and an integrin receptor antagonist).
Among biologic-naïve patients, a statistically significant higher proportion of patients achieved clinical remission at Week 10 when treated with filgotinib 200 mg (26.1 percent, p=0.0157) compared with placebo (15.3 percent). Among biologic-experienced patients, a statistically significant higher proportion of patients achieved clinical remission at Week 10 when treated with filgotinib 200 mg (11.5 percent, p=0.0103) compared with placebo (4.2 percent).
Grab Your Report at an Impressive Discount @ https://www.businessindustryreports.com/check-discount/267993 .
Major Points in Table of Contents:
Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Report 2020
1 Non-alcoholic Steatohepatitis (NASH) Biomarkers Product Definition
2 Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Manufacturer Share and Market Overview
2.1 Global Manufacturer Non-alcoholic Steatohepatitis (NASH) Biomarkers Shipments
2.2 Global Manufacturer Non-alcoholic Steatohepatitis (NASH) Biomarkers Business Revenue
2.3 Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Overview
2.4 COVID-19 Impact on Non-alcoholic Steatohepatitis (NASH) Biomarkers Industry
3 Manufacturer Non-alcoholic Steatohepatitis (NASH) Biomarkers Business Introduction
3.1 Biopredictive Non-alcoholic Steatohepatitis (NASH) Biomarkers Business Introduction
3.2 Quest Diagnostics Non-alcoholic Steatohepatitis (NASH) Biomarkers Business Introduction
3.3 Exalenz Bioscience Non-alcoholic Steatohepatitis (NASH) Biomarkers Business Introduction
3.4 GENFIT Non-alcoholic Steatohepatitis (NASH) Biomarkers Business Introduction
3.5 Siemens Healthineers Non-alcoholic Steatohepatitis (NASH) Biomarkers Business Introduction
3.6 ONE WAY LIVER Non-alcoholic Steatohepatitis (NASH) Biomarkers Business Introduction
About us
BusinessindustryReports.com is digital database of comprehensive market reports for global industries. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined – we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves.
Media Contact
Business Industry Reports
Pune – India
sales@businessindustryreports.com
+19376349940
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Rapidly Increasing In Size Globally (2020-2025) and Market Analysis by Gilead, Biopredictive, Quest Diagnostics, Exalenz Bioscience, GENFIT here
News-ID: 2066616 • Views: …
More Releases from Business Industry Reports
Tetracaine Market Exhibits a Lucrative Growth Potential during 2021-2025 | Endo …
BusinessIndustryReports has recently broadcasted a new study to its broad research portfolio, which is titled as “Global Tetracaine Market” Research Report 2021 provides an in-depth analysis of the Tetracaine with the forecast of market size and growth. The analysis includes addressable market, market by volume, market share by business type and by segment (external and in-house). The research study examines the Tetracaine on the basis of a number of criteria,…
Cyber Warfare Market Evenly Poised To Reach A Market Value of US$ By Share, Size …
Overview of Global Cyber Warfare Market:
This report provides in-depth study of “Global Cyber Warfare Market 2021” using SWOT analysis i.e. Strength, Weakness, Opportunities, and Threat to the organization. The Cyber Warfare Market report also provides an in-depth survey of key players in the market organization.
According to the market research study, the Cyber Warfare is virtual conflict between state, organization, or country by the use of computer technology to disrupt activities…
Covid-19 Impact on Cranio Maxillofacial Implant Market 2021-2025: Business Growt …
Overview of Global Cranio Maxillofacial Implant Market:
This report provides in-depth study of “Global Cranio Maxillofacial Implant Market 2021” using SWOT analysis i.e. Strength, Weakness, Opportunities, and Threat to the organization. The Cranio Maxillofacial Implant Market report also provides an in-depth survey of key players in the market organization.
According to the market research study, Craniomaxillofacial Implants are medical implants used in surgeries of maxillofacial region such as, head, face, neck, oral,…
Beginning of the bloom: The Rise of the Biohacking Market 2021-2025 | Global Key …
Global Biohacking Market Synopsis:
The report covers a forecast and an analysis of the Biohacking Market on a global and regional level. The study provides historical data for 2015, 2016, 2017 and 2018 along with a forecast from 2020 to 2025 based on revenue (USD Million) and volume (Kilotons). The study includes drivers and restraints of the Biohacking Market along with the impact they have on the demand over the forecast…
More Releases for NASH
Nonalcoholic Steatohepatitis (NASH) Market Massive Growth opportunity Ahead
Introduction
Nonalcoholic Steatohepatitis (NASH) is an advanced form of nonalcoholic fatty liver disease (NAFLD) characterized by fat accumulation in the liver along with inflammation and liver cell damage. If left untreated, NASH can progress to fibrosis, cirrhosis, liver failure, or hepatocellular carcinoma. Closely tied to the global obesity and diabetes epidemic, NASH has become a major healthcare burden, with millions affected worldwide and no widely approved curative therapy to date.
The NASH…
Non-Alcoholic Steatohepatitis (NASH) - Drug Pipeline Landscape, 2023
Nonalcoholic steatohepatitis (NASH) is a type of fatty liver disease. It is characterized by the accumulation of fat in the liver, inflammation, and damage. NASH can lead to cirrhosis, liver failure, and death. The exact cause of NASH is unknown, but it is believed to be associated with obesity, insulin resistance, and diabetes. Treatment of NASH is focused on weight loss, exercise, and the control of diabetes and insulin resistance.
NASH…
Non Alcoholic Steatohepatitis (NASH) Market Size to Hit $21,879 Million by 2028 …
According to our experience research team, Non Alcoholic Steatohepatitis (NASH) Market was valued at USD 1,569 Million in 2021, and the global Non Alcoholic Steatohepatitis (NASH) industry is projected to reach a value of USD 21,879 Million by 2028, at a CAGR of 60.4% during the forecast period 2022-2028
The report is focused on gaining various Non Alcoholic Steatohepatitis (NASH) market trends, dynamics, growth drivers, opportunities, weaknesses, strengths, and threats restraining…
NASH Market Insight and Landscape report
Report Snapshot:
NASH is one of the furthermost causes of liver disease worldwide and will probably emerge as the leading cause of end-stage liver disease in the coming years, with the disease affecting both adults and children. The epidemiology and demographic characteristics of NASH vary across different country level. Furthermore, individuals with NAFLD have a high frequency of metabolic comorbidities and could place a growing strain on health-care systems from their…
Nash releases debut EP 'She Don't Know'
London-based singer/songwriter Nash has released his debut EP She Don’t Know. Recorded at the legendary RAK Studios, She Don’t Know has the feel of 60s rock but with a modern twist, leaving the listener hooked throughout and wanting to come back for another listen. She Don’t Know’s leading single CK is an infectious number which is sure to be a hit for 2017.
Listening to the Beatles and Jack White growing…
Nash Technologies at GITEX/GULFCOMMS 2010
Harvey Nash subsidiary presents expert services to telecom operators in the Middle East, Africa and South Asia region
Nürnberg/Germany, 10th September 2010 – For the first time Nash Technologies will be present at GITEX/GULFCOMMS, the largest international trade event for mobile, fixed, IP and satellite communications for the Middle East, Africa and South Asia region, in Dubai from 17th to 21st October 2010 offering its telecom expert services. Nash Technologies will…
